Skip to content
Turning Cold Tumors Hot episode artwork

Jan 9, 2020 22 min

Turning Cold Tumors Hot

from The Bio Report Hosted by Levine Media Group

One reason immunotherapies fail is because of the ability to tumors to alter the microenvironment in which they exist and hide themselves from detection by the immune system. In some indications, as few as 20 percent of patients benefit from checkpoint inhibitors. Oncolytics Biotech is developing pelareorep, an immune-oncolytic virus that activates the innate and adaptive immune systems, triggering inflammation in the tumor, and overexpressing checkpoints to increase the number of patients that can benefit from the use of checkpoint inhibitors. We spoke to Matt Coffey, president and CEO of Oncolytics Biotech, about Pelareorep, how it works to treat cancer, and why it can make checkpoint inhibitors more effective.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Turning Cold Tumors Hot

0:00 22:12

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of The Bio Report?

This episode is 22 minutes long.

When was this The Bio Report episode published?

This episode was published on January 9, 2020.

Can I download this The Bio Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.